Press release
Myopia Pipeline 2024 | Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics
Discover the latest drugs and treatment options in the Myopia Pipeline. Dive into DelveInsight's comprehensive report today! @ Myopia Pipeline Outlook [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Myopia Pipeline Report
* July 2024:- Hoffmann-La Roche - This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled study evaluating the efficacy and safety of faricimab in patients with myopic choroidal neovascularization (CNV). This non-inferiority study will compare 6.0 mg faricimab versus 0.5 mg ranibizumab administered at a pro-re-nata (PRN) dosing regimen after an initial active IVT treatment administration at randomization (Day 1).
* July 2024:- VIS Inc. - The goal of this clinical trial is to evaluate the safety and efficacy of using the VIS Opti-K System to enable monovision by providing temporary improvement in near vision through the treatment of the non-dominant eye of low myopic, emmetropic and low hyperopic presbyope subjects. The main questions it aims to answer are determining uncorrected near visual acuity at 40cm in the treated eye and subjective improvement as measured by the patient satisfaction questionnaire.
* DelveInsight's Myopia pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Myopia treatment.
* The leading Myopia Companies such as Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics , and others.
* Promising Myopia Therapies such as SYD-101 Dose 1, Alleance, NVK-002 Concentration 1, QLM3004 Concentration 1, Atropine Sulfate 01, and others.
Stay ahead with the most recent pipeline outlook for Myopia. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Myopia Treatment Drugs [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Myopia Emerging Drugs Profile
* Atropine micro-formulation (MicroPine): Eyenovia
MicroPine is a proprietary microdose formulation of atropine used in our Optejet dispenser and product candidate for the prevention of progressive myopia (nearsightedness) in children. It is believed that Eyenovia's delivery technology is particularly well-suited for this application and patient population, potentially enabling children to easily self-administer atropine medication while minimizing dose-related side effects. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Myopia.
* SYD-101: Sydnexis
SYD-101 is an investigational low-dose atropine sulfate ophthalmic solution, 0.01% and 0.03%, designed to achieve efficacy, stability, and reduce discomfort for improved treatment continuity, according to studies on the treatment of childhood myopia. While published reports have shown low concentrations of compounded atropine to be effective, these solutions are limited by short shelf life and remain only stable if markedly acidified, which can also cause excessive burning and stinging in children, according to several studies on atropine for myopia. Currently, the drug is in phase III stage of its clinical trial for the treatment of Myopia.
Explore groundbreaking therapies and clinical trials in the Myopia Pipeline. Access DelveInsight's detailed report now! @ New Myopia Drugs [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Myopia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Intra-articular
* Intraocular
* Intrathecal
* Intravenous
* Ophthalmic
* Oral
* Parenteral
* Subcutaneous
* Topical
* Transdermal
Myopia Products have been categorized under various Molecule types such as
* Oligonucleotide
* Peptide
* Small molecule
Unveil the future of Myopia Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Myopia Market Drivers and Barriers [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Myopia Pipeline Report
* Coverage- Global
* Myopia Companies- Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics, and others.
* Myopia Therapies- SYD-101 Dose 1, Alleance, NVK-002 Concentration 1, QLM3004 Concentration 1, Atropine Sulfate 01, and others.
* Myopia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Myopia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Myopia Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Myopia Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/myopia-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Myopia: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Myopia - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Atropine micro-formulation (MicroPine): Eyenovia
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Myopia - Collaborations Assessment- Licensing / Partnering / Funding
* Myopia - Unmet Needs
* Myopia - Market Drivers and Barriers
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myopia-pipeline-2024-sydnexis-sunhawk-vision-biotech-vyluma-eyenovia-cloudbreak-therapeutics-stuart-therapeutics]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myopia Pipeline 2024 | Sydnexis, Sunhawk Vision Biotech, Vyluma, Eyenovia, Cloudbreak Therapeutics, Stuart Therapeutics here
News-ID: 3611312 • Views: …
More Releases from ABNewswire
Full Body Checkup The Gateway to Proactive Health
A full body checkup is one of the most thorough and proactive approaches to taking control of your long-term health. By regularly evaluating all major bodily systems and risk factors, a full body checkup helps to identify potential problems before symptoms develop, granting you the opportunity to stay healthy and empowered. At Liv Hospital [https://int.livhospital.com/], patients benefit from advanced diagnostics, experienced specialists, and patient-centered comfort throughout the process, making routine…
Andy DeFrancesco on Market Cycles, Business Mindset, and the Future of the Busin …
Image: https://www.abnewswire.com/upload/2025/11/d35dbae4dbd114c90cd75748c7d93c3c.jpg
Market optimism rises and falls in waves, but the people who shape industries rarely move with emotion. They study patterns, look beyond the noise, and respond to momentum before the crowd recognizes it. Andy DeFrancesco [https://www.linkedin.com/authwall?trk=bf&trkInfo=AQGgt6lQ4W3QHgAAAZqcxvlI_dUN8oxVB90MzEZ8iE-RruFwmtW1mgWieTjNpqt9TfGmpIboUWLMgp2cCS3U44ppQA-fyWs0h6Op-uvqdNuDq7e6HJhMneocPYkXhKrOLhPDFUM=&original_referer=&sessionRedirect=https%3A%2F%2Fwww.linkedin.com%2Fin%2Fandy-defrancesco-77584930a] has spent his entire career doing exactly that. After decades in public markets, private equity, and emerging sectors, he has learned that the numbers matter - but the psychology behind them matters more.
Business…
The Current Business Landscape: A High-Stakes, Tech-Driven Era
In 2025, the global business environment is shaped by a complex interplay of technology, economic pressures, and evolving market expectations. While inflation and cost control remain real concerns for many companies, digital transformation and cyber risk are dominating boardroom conversations. Business leaders increasingly cite artificial intelligence, cybersecurity, and cost management as their top priorities.
At the same time, the pace of technology adoption continues to accelerate. Small and midsize businesses are…
Contrarian Watch Company Launches Swiss-Made Luxury Timepieces for Those Who Dar …
Contrarian Watch Company debuts with a mission to redefine accessible luxury through Swiss-made timepieces that blend precision craftsmanship with bold design. The collection targets individuals who refuse to follow trends, offering top-quality watches that make statements this holiday season and beyond.
As holiday shopping season begins and consumers seek meaningful gifts that convey sophistication and thought, a new player in the luxury watch market is challenging industry conventions. Contrarian Watch Company…
More Releases for Myopia
Myopia Market Assessment & Forecast: Strategic Insights into Pediatric Myopia Ma …
Albany, United States - September 25, 2025 - DelveInsight, a leading provider of market intelligence and strategic consulting services in the healthcare sector, has released a comprehensive case study report on Myopia Market Assessment & Forecast, providing in-depth insights into the pediatric myopia landscape across Asia. This detailed study highlights prevalence trends, treatment paradigms, and market opportunities, equipping stakeholders with the actionable intelligence required to make informed decisions in the…
Myopia Control Lenses Market Forecast to Expand at 16.2% CAGR Amid Increasing Pe …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Myopia Control Lenses Market- (By Lens Type (Multifocal Lenses, Orthokeratology Lenses, Dual-Focus Lenses, Peripheral Defocus Lenses), By Age Group (Children, Adults), By Distribution Channel (Optometry Clinics, Optical Retail Stores, Online Retail)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Global Myopia Control Lenses Market is valued…
Myopia Control Lenses Market Size to Grow with Rising Prevalence of Childhood My …
The latest Myopia Control Lenses Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2025 and 2032. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The Industry compass guiding business through the complexities of the market, presenting not only the current landscape but also the latest innovations shaping its…
Myopia Control Devices Market - Seeing Beyond Blur: Revolutionary Myopia Devices …
Newark, New Castle, USA: The "Myopia Control Devices Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Myopia Control Devices Market: https://www.growthplusreports.com/report/myopia-control-devices-market/7989
This latest report researches the industry structure,…
Myopia Control Devices Market - Unlocking the Future of Clear Sight: Myopia Cont …
Newark, New Castle, USA - new report, titled Myopia Control Devices Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Myopia Control Devices market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Myopia Control Devices market. The report offers an overview of…
The Myopia Market is expected to be driven by the factors such as the rising cas …
The Myopia market is expected to show positive growth, mainly attributed to the increased diagnosed prevalence and also, the launch of upcoming devices during the forecast period. Moreover, advances in disease mechanisms have yielded new diagnostic and treatment approaches, opening avenues to better treatment interventions.
The Myopia market report provides current treatment practices, emerging drugs, Myopia market share of the individual therapies, current and forecasted Myopia market Size from 2019 to…
